Outcomes of Rezum water vapor therapy for benign prostate obstruction with 1-year follow-up: Largest real-world data from Turkey.

INTRODUCTION

The study aimed to retrospectively assess the safety and efficacy of Rezum, a promising minimally invasive treatment method for BPH, in patients treated at our clinic.

MATERIAL AND METHODS

From January 1, 2022, to December 31, 2022, a cohort of 71 patients presenting with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) were enrolled in the study. These individuals opted for Rezum therapy as their treatment approach. Primary outcome measures included the International Prostate Symptom Score (IPSS), maximum flow rate (Q), post-void residual volume (PVR), Quality of Life (QoL), prostate volume (PV), prostate-specific antigen (PSA), and the International Index of Erectile Function (IIEF) questionnaire.

RESULTS

The median age of the 71 patients was 62.1 ±9.3 years, with a median PV of 60.4 ±16.6 ml. Preoperatively, IPSS was 21.9 ±5.2, Q was 9.67 ±3.2, QoL was 3.35 ±0.61, IIEF-5 was 23.9 ±5.4, total PSA was 2.43 ±1.27 ng/ml, and PVR was 177.4 ±216.5 ml. At the 3-month follow-up, IPSS improved to 10.1 ±5.6, Q to 24.5 ±3.7, QoL to 1.2±0.51, IIEF-5 to 24.5 ±5.4, total PSA to 1.8 ±0.9 ng/ml, and PVR remained at 177.4 ±216.5 ml. At the 12-month follow-up, IPSS was 6.0 ±3.1, Q was 18.12 ±3.7, QoL was 1.2 ±0.51, IIEF-5 was 24.5 ±5.4, total PSA was 1.8 ±0.9 ng/ml, and PVR was 24.9 ±25.2 ml.

CONCLUSIONS

Rezum therapy is a safe, effective, and minimally invasive option for the treatment of men with moderate to severe lower urinary tract symptoms (LUTS).